Investors got the chance to get up close and personal with ASX technology and biotech companies in Sydney recently at the JMM & Ethica Capital Innovation & Investment Insights Lunch.
Featuring quick ‘stand up and pitch your story’ style presentations investors were also given the opportunity to mingle and ask questions of those leading some of the Aussie bourse’s most innovative tech and biotech companies.
But don’t feel you missed out. Here’s a highlight of the companies and what their leaders had to say.
4DS Memory (ASX:4DS) is a semiconductor company pioneering a new type of non-volatile memory known as Interface Switching ReRam, which delivers high endurance memory with extremely fast write times and tunable persistence for emerging AI processor applications.
4DS owns a vast patented IP portfolio, comprising 34 USA patents, and is the first company to develop Area based ReRam, also known as PCMO, on an advanced CMOS processing node.
“We’re building a kind of memory that will unblock the bottlenecks in really computer intensive applications, so AI comes to mind as an example,” non-executive chairman Howard Digby says.
Here is Digby to explain more:
BCal Diagnostics (ASX:BDX) is developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost effective and accurate alongside traditional screening methods.
Executive chair Jayne Shaw says the company has been working on research and development for the past 14 years and has comprehensive scientific data with plans to launch the test in Australia later in 2024.
“It’s very exciting we’ll get it right in Australia, fine tune it and then take it to the US and hopefully to the rest of the world,” Shaw says.
Here is Shaw to explain more:
BlinkLab (ASX:BB1) listed on the ASX in April and is developing an App using technology from Princeton University which turns an ordinary mobile phone into a device for conducting neurobehavioral evaluations.
Non-executive chairman Brian Leedman says the App can conduct a range of neurobehavioral evaluations, including prepulse inhibition, eyeblink conditioning, and startle habituation to assess brain function.
“The conditions we are targeting are autism and ADHD but we believe we can diagnose other neurological disorders and will be doing further study into those as well,” he says.
Here is Leedman to explain more:
Cynata Therapeutics (ASX:CYP) is a clinical-stage stem cell and regenerative medicine company focussed on development and commercialisation of a proprietary induced pluripotent stem cell (iPSC)-based platform technology, Cymerus.
CEO and managing director Dr Kilian Kelly says the Cymerus platform use iPSC technology to enable scalable manufacture of Mesenchymal stem cells (also known as mesenchymal stromal cells or MSCs) products for human use.
“We can make essentially a limitless number of doses from a single blood donation so can avoid the challenges of having to rely on new donors and it’s a real game changer for how these therapies are made,” he says.
Here is Kelly to explain more:
Elsight (ELS) listed on the ASX in 2017 pivoting from a project to product company that now provides high bandwidth, AI-powered connectivity solutions for drones, UAVs, and unmanned autonomous systems.
CEO Yoav Amitai says ELS’s communication technology Halo enables unmanned aircraft to fly beyond the visual line of sight (BVLOS).
“We are focused on specific industries where we have the biggest value proposition,” he says.
“We see the business growing month over month and quarter over quarter and year over year.”
Here is Amitai to explain more:
Imugene (ASX:IMU) is a clinical stage immuno-oncology company working to develop a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.
CEO and managing director Leslie Chong says IMU products work to unleash a person’s immune system and hopefully lead to a cancer cure along with viruses that are also helpful in attacking tumours.
“We are trying to alleviate the scourge of cancer and have a product we call Azer-cel, which is allogeneic CAR T that go against certain type of blood cancers and maybe provide a long-term cure for lymphoma so that is our priority product,” she says.
Here is Chong to explain more:
Praemium (ASX:PPS) started in 2001 as a spinoff from technology that had been developed by JBWere to offer to the market more broadly a SaaS to track, monetise and optimise trading portfolios.
CFO David Coulter said the technology was then adapted to a platform solution for advisors and the company has become well known for its innovations in wealth management.
“In 2020 we acquired a business called Powerwrap, which works off our technology, and more recently in 2024 acquired OneVue, which has got us to our reasonably scaled position,” he says.
Here is Coulter to explain more:
WhiteHawk (ASX:WHK) is the first global online artificial intelligence (AI) and machine learning (ML) based cyber security exchange enabling all businesses and organisations to take smart action to prevent cybercrime, fraud and disruption.
Founder and CEO Terry Roberts says hackers can develop new campaigns within a few hours so traditional manual cybersecurity approaches can’t keep up and aren’t working.
“Using AI and ML we’ve gone from basic to advanced approaches so that we can scan thousands of data sets in just a few minutes and that gives power back to the business clients,” she says.
Here is Roberts to explain more:
The post Up close and personal with ASX tech and Biotech appeared first on Stockhead.
